Vipivotide tetraxetan Linker (PSMA-617 Linker) is a noncleavable peptide linker utilized in the synthesis of Vipivotide tetraxetan (PSMA-617), a ligand instrumental in producing 177Lu-PSMA-617. This radioactive molecule is applied in the treatment of prostate cancer[1].
Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for antibody-drug conjugates (ADCs) that combines the ADC linker (Acetylene-linker-Val-Cit-PABC) with the potent tubulin inhibitor MMAE.
CCK2R Ligand-Linker Conjugate 1 is a hydrophilic peptide linker that conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) as ligand-linker conjugates[1].
CL2 Linker is a cleavableADC linker. CL2-SN-38 and CL2A-SN-38 are equivalent in drug substitution (~6), cell binding (Kd ~1.2 nM), cytotoxicity (IC50 ~2.2 nM), and serum stability in vitro (t1 2 ~20 hours)[1][2].
cIAP1 Ligand-Linker Conjugates 11 Hydrochloride is a chemical compound consisting of an IAP ligand that targets the E3 ubiquitin ligase, along with a PROTAC linker. It is primarily utilized in the development of SNIPERs, a molecular tool for targeted protein degradation[1].
cIAP1 Ligand-Linker Conjugates 11 is a chemical compound that combines an IAP ligand specifically designed for the E3 ubiquitin ligase with a PROTAC linker. This compound, cIAP1 Ligand-Linker Conjugates 11, is useful in the development of SNIPERs[1], allowing for the targeted degradation of proteins.